PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Polaryx Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.92+0.04 (+2.13%)
Close on Oct 19, 2026
- Market cap
- $92.69M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$6.99 (−78.45%)since Feb 6, 2026
Weekly closes, adjusted for splits, on a log scale. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $92.69M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 8.47
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$8.99M
- EPS, diluted
- -$0.20
- Book value per share
- $0.23
- Diluted shares
- 48M
Three years at a glance
Fiscal years 2023 to 2025, USD
Operating income
-$7.82M
Net income
-$8.99M
EPS, diluted
-$0.20
Reported period